There are 2789 resources available
LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial
Presenter: Jason Luke
Session: Presidential symposium 1
Resources:
Abstract
Slides
Webcast
What is immuno-oncology, what are the latest therapies, and what is the role of gene therapies
Presenter: Alan Melcher
Session: Progress in immuno-oncology
Resources:
Webcast
Immuno-oncology: The latest scientific findings and future perspectives
Presenter: Piotr Wysocki
Session: Progress in immuno-oncology
Resources:
Slides
Webcast
Precision immunotherapy: Soon a daily reality?
Presenter: Ulrich Keilholz
Session: Progress in immuno-oncology
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Tanja Spanic
Session: Progress in immuno-oncology
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Emilie Le Rhun
Session: Should radiotherapy be considered for the initial treatment of brain metastases regarding its possible immunogenic booster effect?
Resources:
Slides
Webcast
Yes
Presenter: Giuseppe Minniti
Session: Should radiotherapy be considered for the initial treatment of brain metastases regarding its possible immunogenic booster effect?
Resources:
Slides
Webcast
No
Presenter: Matthias Preusser
Session: Should radiotherapy be considered for the initial treatment of brain metastases regarding its possible immunogenic booster effect?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Emilie Le Rhun
Session: Should radiotherapy be considered for the initial treatment of brain metastases regarding its possible immunogenic booster effect?
Resources:
Slides
Webcast
Q&A
Presenter: Emilie Le Rhun
Session: Should radiotherapy be considered for the initial treatment of brain metastases regarding its possible immunogenic booster effect?
Resources:
Slides
Webcast